• Price (EUR)102.85
  • Today's Change-4.85 / -4.50%
  • Shares traded10.00
  • 1 Year change-26.68%
  • Beta--
Data delayed at least 15 minutes, as of Jun 09 2023 14:52 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Revvity, Inc. is a provider of products, services and solutions for the diagnostics and life sciences. The Company is focused on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics, and more. Its Life Sciences segment provides products and services targeted towards the life sciences market. Its Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. Its portfolio includes research and development (R&D), clinical and diagnostics, platforms and automation, signals software, and advanced services and licensing. It offers genomic analysis, protein analysis, cell analysis, and research solutions. It offers clinical and diagnostics in the field of reproductive health, infectious diseases, autoimmunity, endocrinology, allergy, cancer, neurodegeneration, and rapid patient testing.

  • Revenue in USD (TTM)2.73bn
  • Net income in USD360.52m
  • Incorporated1947
  • Employees16.70k
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.